BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 28008145)

  • 1. MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial.
    Levallet G; Dubois F; Fouret P; Antoine M; Brosseau S; Bergot E; Beau-Faller M; Gounant V; Brambilla E; Debieuvre D; Molinier O; Galateau-Sallé F; Mazieres J; Quoix E; Pujol JL; Moro-Sibilot D; Langlais A; Morin F; Westeel V; Zalcman G
    Oncotarget; 2017 Jan; 8(3):4313-4329. PubMed ID: 28008145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein expression and methylation of DNA repair genes hMLH1, hMSH2, MGMT and BRCA1 and their correlation with clinicopathological parameters and prognosis in basal-like breast cancer.
    Alkam Y; Mitomi H; Nakai K; Himuro T; Saito T; Takahashi M; Arakawa A; Yao T; Saito M
    Histopathology; 2013 Nov; 63(5):713-25. PubMed ID: 24004112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of DNA double-strand break repair proteins ATM and BRCA1 predicts survival in colorectal cancer.
    Grabsch H; Dattani M; Barker L; Maughan N; Maude K; Hansen O; Gabbert HE; Quirke P; Mueller W
    Clin Cancer Res; 2006 Mar; 12(5):1494-500. PubMed ID: 16533773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
    Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC
    Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients.
    Sharma G; Mirza S; Parshad R; Srivastava A; Gupta SD; Pandya P; Ralhan R
    Life Sci; 2010 Jul; 87(3-4):83-91. PubMed ID: 20470789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy.
    Xie KJ; He HE; Sun AJ; Liu XB; Sun LP; Dong XJ
    Asian Pac J Cancer Prev; 2014; 15(6):2591-6. PubMed ID: 24761869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial.
    de Fraipont F; Levallet G; Creveuil C; Bergot E; Beau-Faller M; Mounawar M; Richard N; Antoine M; Rouquette I; Favrot MC; Debieuvre D; Braun D; Westeel V; Quoix E; Brambilla E; Hainaut P; Moro-Sibilot D; Morin F; Milleron B; Zalcman G;
    Clin Cancer Res; 2012 May; 18(10):2976-86. PubMed ID: 22434665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of DNA mismatch repair proteins MLH1, MSH2, and MSH6 in recurrent glioblastoma.
    Stark AM; Doukas A; Hugo HH; Hedderich J; Hattermann K; Maximilian Mehdorn H; Held-Feindt J
    Neurol Res; 2015 Feb; 37(2):95-105. PubMed ID: 24995467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive analysis of DNA repair gene polymorphisms and survival in patients with early stage non-small-cell lung cancer.
    Kim M; Kang HG; Lee SY; Lee HC; Lee EB; Choi YY; Lee WK; Cho S; Jin G; Jheon HS; Son JW; Lee MH; Jung DK; Cha SI; Kim CH; Kang YM; Kam S; Jung TH; Jheon S; Park JY
    Cancer Sci; 2010 Nov; 101(11):2436-42. PubMed ID: 20731661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients.
    Nakai K; Mitomi H; Alkam Y; Arakawa A; Yao T; Tokuda E; Saito M; Kasumi F
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):923-30. PubMed ID: 22083523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection.
    Kang CH; Jang BG; Kim DW; Chung DH; Kim YT; Jheon S; Sung SW; Kim JH
    Lung Cancer; 2010 Jun; 68(3):478-83. PubMed ID: 19683826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer.
    Kamal NS; Soria JC; Mendiboure J; Planchard D; Olaussen KA; Rousseau V; Popper H; Pirker R; Bertrand P; Dunant A; Le Chevalier T; Filipits M; Fouret P;
    Clin Cancer Res; 2010 Feb; 16(4):1206-15. PubMed ID: 20145178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer.
    Lee MN; Tseng RC; Hsu HS; Chen JY; Tzao C; Ho WL; Wang YC
    Clin Cancer Res; 2007 Feb; 13(3):832-8. PubMed ID: 17289874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
    Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of DNA repair proteins, MSH2, MLH1 and MGMT in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients' survival.
    Theocharis S; Klijanienko J; Giaginis C; Rodriguez J; Jouffroy T; Girod A; Point D; Tsourouflis G; Sastre-Garau X
    J Oral Pathol Med; 2011 Mar; 40(3):218-26. PubMed ID: 21029181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of MSH2 expression by an Hsp90 inhibitor enhances pemetrexed-induced cytotoxicity in human non-small-cell lung cancer cells.
    Tung CL; Chiu HC; Jian YJ; Jian YT; Chen CY; Syu JJ; Wo TY; Huang YJ; Tseng SC; Lin YW
    Exp Cell Res; 2014 Apr; 322(2):345-54. PubMed ID: 24530475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of DNA repair proteins MLH1, MSH2 and MGMT expression in non-small-cell lung cancer and precursor lesions.
    Cooper WA; Kohonen-Corish MR; Chan C; Kwun SY; McCaughan B; Kennedy C; Sutherland RL; Lee CS
    Histopathology; 2008 Apr; 52(5):613-22. PubMed ID: 18370958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [DNA repair pathways and non-small cell lung cancer: clinical perspectives].
    Olaussen KA; Planchard D; Adam J; Soria JC
    Bull Cancer; 2011 Mar; 98(3):305-22. PubMed ID: 21459711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression.
    Bartolucci R; Wei J; Sanchez JJ; Perez-Roca L; Chaib I; Puma F; Farabi R; Mendez P; Roila F; Okamoto T; Taron M; Rosell R
    Clin Lung Cancer; 2009 Jan; 10(1):47-52. PubMed ID: 19289372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylation of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients.
    Fumagalli C; Pruneri G; Possanzini P; Manzotti M; Barile M; Feroce I; Colleoni M; Bonanni B; Maisonneuve P; Radice P; Viale G; Barberis M
    Breast Cancer Res Treat; 2012 Jul; 134(1):131-7. PubMed ID: 22228432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.